What is the incidence of methicillin‑resistant Staphylococcus aureus (MRSA) sepsis in neonatal intensive care units, particularly among very‑low‑birth‑weight (<1500 g) preterm infants?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 19, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

MRSA Sepsis Incidence in the NICU

MRSA sepsis in the NICU has increased substantially over the past two decades, with late-onset MRSA infections rising 308% from 0.7 to 3.1 per 10,000 patient-days between 1995 and 2004, though the current epidemiologic landscape shows significant geographic variation and ongoing challenges with transmission despite active surveillance. 1

Current Incidence Data

The most comprehensive surveillance data demonstrates that MRSA accounts for approximately 23% of all Staphylococcus aureus infections in NICUs, with methicillin resistance testing available for the majority of isolates 1. Among infants with S. aureus bacteremia specifically, 47% had MRSA infection in tertiary care NICUs, representing a substantial disease burden 2.

Distribution by Infection Type

Among MRSA infections in neonates, the breakdown is:

  • 31% are bloodstream infections (sepsis) 1
  • 18% are pneumonia 1
  • 17% are conjunctivitis 1

This distribution remained stable over the surveillance period, indicating that bloodstream infections consistently represent the largest proportion of MRSA disease in this population 1.

Risk Factors and High-Risk Populations

All birthweight categories experienced significant increases in MRSA infection rates, including very-low-birth-weight infants (<1000g), low-birth-weight infants (1001-1500g), and even larger neonates 1. Very-low-birth-weight and preterm infants remain at particularly high risk due to underdeveloped immune systems, compromised skin barriers, and frequent use of invasive medical devices 3.

Clinical Severity and Outcomes

MRSA sepsis in neonates presents with severe disease: 88% of infected infants presented in septic shock, with a mortality rate of 38% despite vancomycin therapy 2. Among colonized neonates, 17% subsequently developed MRSA infection, and this occurred even in units with active surveillance and decolonization protocols 4.

Transmission Dynamics and Prevention Challenges

Ongoing Transmission Despite Interventions

Even with comprehensive MRSA control programs including weekly surveillance cultures and decolonization protocols, 2.0% of all NICU admissions acquired MRSA, with transmission continuing despite these measures 4. Critically, 8 of 19 neonates (42%) with MRSA infections became infected before they were identified as colonized, highlighting the limitations of current surveillance strategies 4.

Decolonization Limitations

Among neonates who underwent decolonization:

  • 16% developed subsequent MRSA infection 4
  • 50% of those remaining in the NICU for ≥21 days became recolonized 4

These data demonstrate that current decolonization regimens are inadequate for sustained MRSA eradication in this vulnerable population 4.

Strain Diversity

Molecular typing reveals significant strain diversity, with 14 different MRSA strain types identified in a single NICU, with USA300 (a community-associated strain) being most common at 31% 4. Notably, 75% of MRSA bacteremia isolates carried SCCmec genes characteristic of community-associated MRSA rather than traditional hospital strains 2, indicating that community strains have successfully invaded the NICU environment and cause severe disease.

Effective Control Measures

Historical data from successful outbreak control demonstrates that elimination of endemic MRSA in NICUs is achievable within 7-9 months when multimodal interventions are implemented, including enhanced hand hygiene with antiseptic agents (1% triclosan), active surveillance cultures, and contact precautions 3. Hand hygiene compliance is particularly critical: each 1% increase in hand hygiene compliance on room entry and exit was associated with hazard ratios of 0.834 and 0.719 for MRSA colonization, respectively 5.

Key Prevention Strategies

Hand hygiene compliance impacts MRSA colonization rates regardless of room configuration (single-patient vs. open-unit), whereas average daily census affects colonization only in single-patient rooms 5. This emphasizes that infection control practices, not physical infrastructure alone, drive outcomes 5.

Canadian guidelines specifically recommend tailored approaches for MRSA outbreak management in NICUs, emphasizing the need for consistency in screening (96% of hospitals screen for MRSA), though only 21% conduct regular prevalence surveys 3.

Critical Pitfalls to Avoid

  • Relying solely on surveillance cultures: Infections occur before colonization is detected in a substantial proportion of cases 4
  • Assuming decolonization provides durable protection: Recolonization rates are high, particularly with prolonged NICU stays 4
  • Ignoring maternal screening: MRSA outbreaks can originate from colonized mothers, making maternal screening an important prevention strategy 6
  • Underestimating disease severity: The high rates of septic shock (88%) and mortality (38%) demand aggressive empirical coverage when MRSA is suspected 2

Geographic and Temporal Considerations

While the 308% increase in MRSA incidence occurred between 1995-2004 1, more recent data suggests the epidemiology continues to evolve with emergence of community-associated strains causing severe neonatal disease 2. The global shift toward Gram-negative pathogens in neonatal sepsis in low- and middle-income countries 3 does not diminish the importance of MRSA in high-resource NICUs, where it remains a significant pathogen requiring ongoing vigilance.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.